Balmer Lawrie & Company Ltd
BALMLAWRIEBalmer Lawrie & Company Ltd's earnings have outrun its stock. EPS grew +4.1% in a year against a −17.3% price move.
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding.
The price is in a downtrend (39 weeks in) while the P/E sits at the 6th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +6.0% year on year, and 94% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Balmer Lawrie & Company Ltd trades at ₹172, in a downtrend and 39 weeks into that stage. That is −6.4% against its own 200-day average. It sits at 20% of a 52-week range of ₹157 to ₹231. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (7 weeks and counting).
Today the stock is in a downtrend — week 39 of stage 4, confirmed. At ₹172 it trades −6.4% versus its 200-day average and sits at 20% of its 52-week range (₹157–₹231).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +91% while the NIFTY 500 moved +276% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (7 weeks and counting; last ahead the week of 2026-06-24) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Balmer Lawrie & Company Ltd trades at 10.6× P/E, near the bottom of its own range — cheaper only 6% of the time. Its long-run median P/E is 13.5×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 10.6× is near the bottom of its own range — cheaper only 6% of the time, against a long-run median of 13.5× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.
Why the multiple sits where it does: over the past year annual EPS moved +4.1% against a −17.3% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +4.9%/yr price move, ~+18.2%/yr came from earnings growth and ~−13.3 pp from the multiple (compressing); over 10y, of the +5.1%/yr price move, ~+6.2%/yr came from earnings growth and ~−1.1 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources disagree by up to 28% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Balmer Lawrie & Company Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 15.0% and holding. The read is built from 8 quarters across 4 curves, on partial evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +8.5% | +5.5% | +12.2% | +5.5% |
| Profit | +4.2% | +17.1% | +18.6% | +5.1% |
| EPS | +4.1% | +17.2% | +18.1% | +5.4% |
| Share price | −17.3% | +4.9% | +4.9% | +5.1% |
4-Factor Sector Score
53.8/100 — rank 8 of 20 in Diversified · 82% evidence confidence
Balmer Lawrie & Company Ltd scores 53.8 out of 100 against the 20 companies it is compared with in Diversified, ranking 8. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 16.6 + 15.3 + 14.5 + 7.4 = 53.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Balmer Lawrie & Company Ltd reported ₹749 Cr of revenue in the Jun 26 quarter, +10.0% year on year. That is the 3rd straight quarter of year-on-year growth. Over 10 years it has compounded at 5.5% a year. The last full year, FY26, came in at ₹2,717 Cr. The last four reported quarters add to ₹2,785 Cr.
FY26 revenue came in at ₹2,717 Cr (+8.5% on the year), capping 10 years at 5.5% compound. The latest quarter (Jun 26) printed ₹749 Cr, +10.0% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +9.0% growth against the decade's 5.5% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +8.9% over the last 4 quarters against +8.0%/yr over the last 8 — stabilising; TTM profit +3.8% vs +1.7%/yr — stabilising.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Balmer Lawrie & Company Ltd's operating margin is 13.0% in the Jun 26 quarter, +1.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged 7.0% to 13.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 13.0%, +1.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 7.0%–13.0%, and FY26's 13.0% is the top of that band — a record year.
Why the margin moved: operating margin went +1.1 pp year on year while gross margin went +1.1 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Balmer Lawrie & Company Ltd earned ₹71.0 Cr of net profit in the Jun 26 quarter, +6.0% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹270 Cr. The 10-year compound rate is 5.1%. That is 9.5% of the quarter's revenue. The same quarter a year earlier earned ₹67.0 Cr.
Jun 26 profit was ₹71.0 Cr, +6.0% year on year — the 3rd consecutive quarter of growth. On the full year, FY26 printed ₹270 Cr (+4.2%), and the 10-year compound rate is 5.1%.
Why profit moved: revenue contributed +10.0% and the margin +1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +3.3% vs revenue +9.0%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 94% of Balmer Lawrie & Company Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹289 Cr of operating cash against ₹270 Cr of profit. After ₹189 Cr of capital spending, ₹100 Cr was left as free cash.
FY26: operating cash of ₹289 Cr against reported profit of ₹270 Cr, leaving free cash of ₹100 Cr after ₹189 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 94% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 94%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 1.7× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Balmer Lawrie & Company Ltd's cash conversion cycle runs 35 days in FY26, up from 28 days in FY21. Capital spending ran ₹324 Cr over the last 3 years. At FY26 sales of ₹2,717 Cr each day of that cycle holds about ₹7.4 Cr, so roughly ₹261 Cr sits inside the business at any moment.
FY26: debtors at 72 days, inventory at 35 days — roughly 1.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 35 days, looser than FY21's 28.
The full loop: cash goes out to suppliers and production on day 0; stock waits 35 days to sell; customers pay about 72 days after that; and suppliers themselves are paid at 71 days — netting out to the 35-day cycle.
In money terms: at FY26 sales of ₹2,717 Cr, each day of the cycle holds about ₹7.4 Cr — so the 35-day loop keeps roughly ₹261 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹324 Cr over the last 3 fiscal years against ₹195 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹34.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Balmer Lawrie & Company Ltd earns a ROCE of 15% in FY26. That is up from a trough of 8% in FY21. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 9.9% net margin on 0.81× asset turns.
FY26 ROCE is 15%, recovered from a FY21 trough of 8% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 9.9% net margin × 0.81× asset turns × 1.62× balance-sheet leverage ≈ 13.0% on equity. Margin does its share; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 28% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Balmer Lawrie & Company Ltd carries ₹220 Cr of borrowings against ₹2,069 Cr of equity in FY26, a debt-to-equity of 0.11. Operating profit covers the interest bill 11×. Over 5 years borrowings went from ₹125 Cr to ₹220 Cr. Capital spending ran ₹324 Cr across the last 3 of those years.
FY26: borrowings of ₹220 Cr against equity of ₹2,069 Cr — a debt-to-equity of 0.11. Operating profit covers the interest bill 11×. Over 5 years borrowings went from ₹125 Cr to ₹220 Cr while capital spending ran ₹324 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 28% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Balmer Lawrie & Company Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved −0.1 points over the same window, to 1.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −0.7 points over 8 quarters to 2.4%; Domestic institutions: −0.1 points over 8 quarters to 1.8%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Balmer Lawrie & Company Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Indiabulls LimitedIBULLSLTD | 61.6/100Mixed-positive evidence67% evidence | LEADER | 18.3/35 Revenue 100% · PAT 100% · OPM change 28 pp 71% evidence | 14.2/25 ROCE 16.2% · OPM 43% 76% evidence | 10.6/20 P/E 13.2× · PEG — 15% evidence | 18.5/20 RS sector 45.4% · RS bench 50.9% · 1Y 82.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.3 + 14.2 + 10.6 + 18.5 = 61.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2BCL Industries LtdBCLIND | 61.0/100Mixed-positive evidence83% evidence | FADING | 19.3/35 Revenue -0.8% · PAT 21.1% · OPM change 2 pp 83% evidence | 14.4/25 ROCE 13.9% · OPM 9% 95% evidence | 13.1/20 P/E 9.4× · PEG — 50% evidence | 14.2/20 RS sector -0.4% · RS bench 4.6% · 1Y -17.6%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 14.4 + 13.1 + 14.2 = 61 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 33M India Ltd3MINDIA | 59.1/100Mixed-positive evidence90% evidence | TURNING | 17.6/35 Revenue 11.5% · PAT -7.5% · OPM change -1.8 pp 88% evidence | 20.0/25 ROCE 40.5% · OPM 17.2% 100% evidence | 11.7/20 P/E 63.8× · PEG 1.25 100% evidence | 9.8/20 RS sector -3.7% · RS bench 3.4% · 1Y 10.8%2 of 10 weeks ahead 70% evidence |
| Exact sum: 17.6 + 20 + 11.7 + 9.8 = 59.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Grasim Industries LtdGRASIM | 57.6/100Mixed-positive evidence78% evidence | LEADER | 22.9/35 Revenue 18.1% · PAT 32.8% · OPM change 1 pp 83% evidence | 12.8/25 ROCE 8% · OPM 21% 76% evidence | 6.7/20 P/E 42.2× · PEG — 50% evidence | 15.2/20 RS sector 2.2% · RS bench 6.9% · 1Y 14.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 22.9 + 12.8 + 6.7 + 15.2 = 57.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Sobhagya Mercantile Ltd512014 | 56.7/100Mixed-positive evidence71% evidence | ASLEEP | 18.6/35 Revenue 49.3% · PAT 41.8% · OPM change -3.7 pp 83% evidence | 18.5/25 ROCE 23.4% · OPM 10.9% 76% evidence | 9.7/20 P/E 43.3× · PEG — 15% evidence | 9.9/20 RS sector -1% · RS bench 3.7% · 1Y 62.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 18.5 + 9.7 + 9.9 = 56.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Texmaco Infrastructure & Holdings LtdTEXINFRA | 55.9/100Mixed-positive evidence76% evidence | LEADER | 24.3/35 Revenue 9.9% · PAT 100% · OPM change 78.8 pp 83% evidence | 5.5/25 ROCE 1.4% · OPM -41.9% 95% evidence | 8.7/20 P/E 133× · PEG — 15% evidence | 17.4/20 RS sector 7.9% · RS bench 12.9% · 1Y 15.7%8 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 5.5 + 8.7 + 17.4 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Kalind Ltd526935 | 55.2/100Mixed-positive evidence67% evidence | BASING | 23.6/35 Revenue — · PAT — · OPM change 21 pp 52% evidence | 18.2/25 ROCE 32% · OPM 63% 76% evidence | 10.6/20 P/E 21.8× · PEG — 50% evidence | 2.8/20 RS sector -84.1% · RS bench 2% · 1Y -44.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 18.2 + 10.6 + 2.8 = 55.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -84.1% and the one-year return is -44.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 8Balmer Lawrie & Company Ltdthis pageBALMLAWRIE | 53.8/100Mixed-positive evidence82% evidence | ASLEEP | 16.6/35 Revenue 8.9% · PAT 3.8% · OPM change 1 pp 95% evidence | 15.3/25 ROCE 14.6% · OPM 13% 76% evidence | 14.5/20 P/E 10.6× · PEG — 50% evidence | 7.4/20 RS sector -13.8% · RS bench -9.4% · 1Y -20.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 15.3 + 14.5 + 7.4 = 53.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Tube Investments of India LtdTIINDIA | 46.1/100Mixed-negative evidence96% evidence | ASLEEP | 18.6/35 Revenue 17.4% · PAT 6.1% · OPM change 2 pp 88% evidence | 17.9/25 ROCE 17.1% · OPM 9% 100% evidence | 2.0/20 P/E 80.6× · PEG 9.63 100% evidence | 7.6/20 RS sector -9.1% · RS bench -4.8% · 1Y -4.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 17.9 + 2 + 7.6 = 46.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 10Nurture Well Industries Ltd531889 | 45.0/100Mixed-negative evidence71% evidence | ASLEEP | 15.8/35 Revenue 34% · PAT 27% · OPM change -9.1 pp 83% evidence | 15.0/25 ROCE 22.9% · OPM 0.2% 76% evidence | 11.5/20 P/E 8.6× · PEG — 15% evidence | 2.7/20 RS sector -21.8% · RS bench -18.1% · 1Y 23.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.8 + 15 + 11.5 + 2.7 = 45 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Bluspring Enterprises LtdBLUSPRING | 43.0/100Thin evidence · provisional57% evidence | TURNING | 18.4/35 Revenue 11.8% · PAT 90.6% · OPM change 0.7 pp 71% evidence | 3.5/25 ROCE 5.1% · OPM 2.2% 95% evidence | 8.9/20 P/E 114× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 51.5% · 1Y 23.7%10 of 10 weeks ahead 25% evidence |
| Exact sum: 18.4 + 3.5 + 8.9 + 12.2 = 43 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Nava LtdNAVA | 41.7/100Mixed-negative evidence89% evidence | ASLEEP | 9.8/35 Revenue 7.8% · PAT -27.6% · OPM change -5 pp 88% evidence | 14.3/25 ROCE 12.8% · OPM 32% 100% evidence | 13.1/20 P/E 20.5× · PEG 1.16 65% evidence | 4.5/20 RS sector -13.4% · RS bench -9.3% · 1Y -9.6%3 of 12 weeks ahead 100% evidence |
| Exact sum: 9.8 + 14.3 + 13.1 + 4.5 = 41.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 13Swan Corp LtdSWANCORP | 35.8/100Thin evidence · provisional58% evidence | ASLEEP | 15.1/35 Revenue -11.5% · PAT -69% · OPM change -31.6 pp 62% evidence | 6.3/25 ROCE 3.9% · OPM -30% 76% evidence | 10.1/20 P/E 35.2× · PEG — 15% evidence | 4.3/20 RS sector -29.3% · RS bench -22.8% · 1Y -35%0 of 10 weeks ahead 70% evidence |
| Exact sum: 15.1 + 6.3 + 10.1 + 4.3 = 35.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Andrew Yule & Company LtdANDREWYU | 34.7/100Thin evidence · provisional55% evidence | TURNING | 13.2/35 Revenue -4.8% · PAT -80% · OPM change -9 pp 62% evidence | 3.5/25 ROCE -6.3% · OPM -52% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.0/20 RS sector -37% · RS bench 13.8% · 1Y -5.2%10 of 11 weeks ahead 70% evidence |
| Exact sum: 13.2 + 3.5 + 10 + 8 = 34.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Integrated Industries LtdIIL | 64.5/100Thin evidence · provisional50% evidence | 20.6/35 Revenue 60.5% · PAT 94.6% · OPM change 2 pp 53% evidence | 16.7/25 ROCE 30.5% · OPM 11% 57% evidence | 11.0/20 P/E 11.6× · PEG — 15% evidence | 16.2/20 RS sector 51.9% · RS bench 63.7% · 1Y 114.3%11 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 20.6 + 16.7 + 11 + 16.2 = 64.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Arunis Abode LtdARUNIS | 50.8/100Thin evidence · provisional45% evidence | 15.3/35 Revenue 100% · PAT 100% · OPM change -17.7 pp 40% evidence | 9.4/25 ROCE -5.3% · OPM 28.5% 57% evidence | 9.4/20 P/E 62.5× · PEG — 15% evidence | 16.7/20 RS sector 131.3% · RS bench 136.7% · 1Y 395.6%12 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 15.3 + 9.4 + 9.4 + 16.7 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Piramal Enterprises Ltd(Merged)PEL | 47.8/100Thin evidence · provisional41% evidence | 19.0/35 Revenue 13.3% · PAT 100% · OPM change -0.7 pp 27% evidence | 11.8/25 ROCE 6.8% · OPM 65.1% 57% evidence | 9.6/20 P/E 49× · PEG — 15% evidence | 7.4/20 RS sector -20.3% · RS bench 1% · 1Y -12.1%6 of 12 weeks ahead to 2025-09-24 70% evidence | |
| Exact sum: 19 + 11.8 + 9.6 + 7.4 = 47.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Bharat Global Developers LtdBGDL | 46.9/100Thin evidence · provisional47% evidence | 15.6/35 Revenue -74% · PAT -80% · OPM change 4.2 pp 53% evidence | 10.8/25 ROCE 11.3% · OPM — 46% evidence | 8.5/20 P/E 291× · PEG — 15% evidence | 12.0/20 RS sector 165.8% · RS bench -70.1% · 1Y -17.1%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 15.6 + 10.8 + 8.5 + 12 = 46.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Rossell India LtdROSSELLIND | 41.1/100Thin evidence · provisional47% evidence | 14.5/35 Revenue 4.8% · PAT -41.1% · OPM change 0.1 pp 36% evidence | 11.0/25 ROCE 6.4% · OPM 10.7% 71% evidence | 10.8/20 P/E 11.8× · PEG — 15% evidence | 4.8/20 RS sector -28.8% · RS bench -19.6% · 1Y -35%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 14.5 + 11 + 10.8 + 4.8 = 41.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Kesar Enterprises LtdKESAR | 33.6/100Thin evidence · provisional42% evidence | 14.2/35 Revenue -55.3% · PAT -80% · OPM change 7.4 pp 40% evidence | 5.9/25 ROCE -26.2% · OPM 2.8% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.5/20 RS sector -44.4% · RS bench -39.4% · 1Y -66.4%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 14.2 + 5.9 + 10 + 3.5 = 33.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Balmer Lawrie & Company Ltd's share price today?
Balmer Lawrie & Company Ltd trades at ₹172, −17.3% over the past year. The company is valued at ₹2,945 Cr. The stock sits at 20% of its 52-week range of ₹157–₹231, −6.4% versus its 200-day average. On the tape, the price is in a downtrend, 39 weeks in. — as of 31 July 2026.
What were Balmer Lawrie & Company Ltd's latest quarterly results?
Balmer Lawrie & Company Ltd reported revenue of ₹749 Cr and net profit of ₹71.0 Cr for the Jun 26 quarter. Revenue rose 10.0% and profit rose 6.0% year on year. Earnings per share were ₹4.18. The operating margin was 13.0%, 1.0 pp higher than a year earlier. — as of 31 July 2026.
What is Balmer Lawrie & Company Ltd's revenue?
Balmer Lawrie & Company Ltd reported revenue of ₹749 Cr in the Jun 26 quarter, +10.0% year on year. For the full FY26 fiscal year, revenue was ₹2,717 Cr (+8.5%). Over the last 10 years revenue compounded at 5.5% a year. — as of 31 July 2026.
What is Balmer Lawrie & Company Ltd's profit?
Balmer Lawrie & Company Ltd earned ₹71.0 Cr of net profit in the Jun 26 quarter, +6.0% year on year — the 3rd straight quarter of growth. Full-year FY26 profit was ₹270 Cr. The operating margin ran 13.0% in the latest quarter. — as of 31 July 2026.
What is Balmer Lawrie & Company Ltd's market cap?
Balmer Lawrie & Company Ltd's market capitalisation is ₹2,945 Cr at a share price of ₹172. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Balmer Lawrie & Company Ltd's P/E ratio?
Balmer Lawrie & Company Ltd trades at a P/E of 10.6×, at the 6th percentile of its own 10-year range, against a long-run median of 13.5×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Balmer Lawrie & Company Ltd pay a dividend?
Yes — Balmer Lawrie & Company Ltd's dividend payout was 26% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Balmer Lawrie & Company Ltd overvalued?
On its own history, Balmer Lawrie & Company Ltd looks cheap against its own history: its P/E of 10.6× has been cheaper only 6% of the time in 10 years (long-run median 13.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 31 July 2026.
Is Balmer Lawrie & Company Ltd growing?
Yes — Balmer Lawrie & Company Ltd is growing: latest-quarter revenue +10.0% year on year, profit +6.0%, and the margin +1.0 pp at 13.0%. The 10-year compound rates are 5.5% (revenue) and 5.1% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Balmer Lawrie & Company Ltd performing?
Balmer Lawrie & Company Ltd is in a downtrend, 39 weeks in. Its latest quarter's revenue rose 10.0% and profit rose 6.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 7 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Balmer Lawrie & Company Ltd in?
Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 15.0% and holding. The read comes from the last 12 quarters of growth (revenue growth +8.9% latest, profit growth +3.8% latest, eps growth +3.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Balmer Lawrie & Company Ltd in an uptrend?
No — the price is in a downtrend (week 39 of stage 4), trading −6.4% versus its 200-day average and at 20% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Balmer Lawrie & Company Ltd beating the market?
Not lately — on a trailing-13-week view Balmer Lawrie & Company Ltd is currently behind the NIFTY 500 (7 weeks and counting; last ahead the week of 2026-06-24), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +91% against the NIFTY 500's +276% — behind the index over the full window. — as of 31 July 2026.
Will Balmer Lawrie & Company Ltd's share price go up?
This page publishes no price forecast for Balmer Lawrie & Company Ltd. What it measures instead: the share price is ₹172, the price is in a downtrend 39 weeks in. Its P/E of 10.6× sits at the 6th percentile of its own 10-year range. — as of 31 July 2026.
Does Balmer Lawrie & Company Ltd have too much debt?
No — Balmer Lawrie & Company Ltd's debt-to-equity is 0.11, and operating profit covers the interest bill 11×. FY26 borrowings were ₹220 Cr against equity of ₹2,069 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Balmer Lawrie & Company Ltd's capex?
Balmer Lawrie & Company Ltd spent ₹324 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹189 Cr, with ₹34.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Balmer Lawrie & Company Ltd's cash flow?
Balmer Lawrie & Company Ltd generated ₹289 Cr of operating cash flow in FY26 and ₹100 Cr of free cash flow after ₹189 Cr of capital spending. Reported profit that year was ₹270 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Balmer Lawrie & Company Ltd's profit real cash?
Yes — over the last 3 fiscal years, 94% of Balmer Lawrie & Company Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹289 Cr against reported profit of ₹270 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Balmer Lawrie & Company Ltd in its business cycle?
Balmer Lawrie & Company Ltd's FY26 operating margin was 13.0%, against a 13-year band of 7.0%–13.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 13.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Balmer Lawrie & Company Ltd story?
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Balmer Lawrie & Company Ltd a stock worth studying right now?
This is not investment advice. The machine read: Balmer Lawrie & Company Ltd's earnings have outrun its stock. EPS grew +4.1% in a year against a −17.3% price move. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.